Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | IMbrave050: adjuvant atezolizumab with bevacizumab in high-risk HCC

Pierce Chow, MBBS, MMed (Surg), FRCS (Edin), FAMS (Gen Surg), PhD, National Cancer Centre Singapore & Duke-NUS Medical School Singapore, Singapore, discusses the Phase III IMbrave050 trial (NCT04102098), of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC). Participants were randomized to receive 17 cycles atezolizumab plus bevacizumab for 1 year, or active surveillance, with crossover possible following recurrence. Recurrence-free survival (RFS), the primary endpoint, was met and no new safety or toxicity concerns were raised. Prof. Chow highlights the potential of this regimen as a new standard of care for HCC in the adjuvant setting. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.